178 related articles for article (PubMed ID: 21924544)
21. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
[TBL] [Abstract][Full Text] [Related]
22. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
23. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
24. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
D'Andrea D; Soria F; Zehetmayer S; Gust KM; Korn S; Witjes JA; Shariat SF
BJU Int; 2019 Jun; 123(6):959-967. PubMed ID: 30653818
[TBL] [Abstract][Full Text] [Related]
26. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
[TBL] [Abstract][Full Text] [Related]
28. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
Aziz A; Shariat SF; Roghmann F; Brookman-May S; Stief CG; Rink M; Chun FK; Fisch M; Novotny V; Froehner M; Wirth MP; Schnabel MJ; Fritsche HM; Burger M; Pycha A; Brisuda A; Babjuk M; Vallo S; Haferkamp A; Roigas J; Noldus J; Stredele R; Volkmer B; Bastian PJ; Xylinas E; May M
BJU Int; 2016 Feb; 117(2):272-9. PubMed ID: 25381844
[TBL] [Abstract][Full Text] [Related]
29. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
30. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria.
Sagnak L; Ersoy H; Gucuk O; Ozok U; Topaloglu H
Urol Int; 2011; 87(1):35-41. PubMed ID: 21654152
[TBL] [Abstract][Full Text] [Related]
32. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria.
Miyanaga N; Akaza H; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Int J Urol; 1999 Apr; 6(4):173-7. PubMed ID: 10226833
[TBL] [Abstract][Full Text] [Related]
33. Detection of bladder cancer using a point-of-care proteomic assay.
Grossman HB; Messing E; Soloway M; Tomera K; Katz G; Berger Y; Shen Y
JAMA; 2005 Feb; 293(7):810-6. PubMed ID: 15713770
[TBL] [Abstract][Full Text] [Related]
34. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.
Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P
Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.
Martini T; Aziz A; Roghmann F; Rink M; Chun FK; Fisch M; Trojan L; Hakenberg OW; Zastrow S; Wirth MP; Moersdorf J; Brookman-May S; Stief CG; Haferkamp A; Wagenlehner F; Hohenfellner M; Herrmann E; Lusuardi L; Grimm MO; Müller SC; Roigas J; Bastian PJ; Gierth M; Burger M; Pycha A; Seitz C; May M; Bolenz C
Urol Int; 2016; 96(1):57-64. PubMed ID: 26139354
[TBL] [Abstract][Full Text] [Related]
36. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
[TBL] [Abstract][Full Text] [Related]
37. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer.
Todenhöfer T; Hennenlotter J; Kühs U; Tews V; Gakis G; Aufderklamm S; Stenzl A; Schwentner C
Urology; 2012 Mar; 79(3):620-4. PubMed ID: 22386412
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
39. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
[TBL] [Abstract][Full Text] [Related]
40. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
